In the field of biopharmaceuticals, artificial intelligence (AI) has become a mature and well-developed tool. However, since the application of AI is primarily focused on the research and development stage rather than downstream commercial operations, there are still significant opportunities for further integration. Meanwhile, many companies are actively exploring how to layer generative AI, including large language models (LLMs) like OpenAI's ChatGPT, on top of existing data and AI models to further improve the new drug development process and enhance operational efficiency.
Thanks for sharing your insights, Meng. It's exciting to see how generative AI and LLMs could further revolutionize drug development and improve operational efficiency. excited to see how these advancements unfold!
In the field of biopharmaceuticals, artificial intelligence (AI) has become a mature and well-developed tool. However, since the application of AI is primarily focused on the research and development stage rather than downstream commercial operations, there are still significant opportunities for further integration. Meanwhile, many companies are actively exploring how to layer generative AI, including large language models (LLMs) like OpenAI's ChatGPT, on top of existing data and AI models to further improve the new drug development process and enhance operational efficiency.
Thanks for sharing your insights, Meng. It's exciting to see how generative AI and LLMs could further revolutionize drug development and improve operational efficiency. excited to see how these advancements unfold!